For patients in the chronic phase of chronic myeloid leukemia, nilotinib and dasatinib showed comparable efficacy as frontline single agents.
Investigators found that dosing of IgRT in CLL at target levels higher than conventional parameters may offer a therapeutic benefit.
Transplant-naive patients were more likely to achieve an optimal drug response — but were also more prone to severe cytokine release syndrome and neurotoxicity.
Progressive telomere shortening during successive cell divisions is thought to contribute to phase transition in chronic myeloid leukemia.
Researchers hypothesized that a combination bispecific mAb in B-cell malignancies could offer a treatment option superior to existing monospecific mAbs.
The feasibility of lenalidomide in combination therapy for chronic lymphocytic leukemia is in question.
Ibrutinib May Be Effective in Patients With Chronic Lymphocytic Leukemia Who Were Excluded from Clinical TrialsAugust 30, 2018
The RESONATE-2 trial excluded certain patients with chronic lymphocytic leukemia, leaving the efficacy and tolerability of ibrutinib in this population unknown.
Albumin-to-fibrinogen ratio may predict poor outcomes in patients with previously untreated chronic lymphocytic leukemia.
No direct comparison between ibrutinib and chemoimmunotherapy as a first-line treatment exists.
Researchers reveal the results of the phase 2 CLL2-BAG trial, which evaluated sequential bendamustine followed by obinutuzumab and venetoclax in patients with CLL.
Researchers sought to determine the impact of intensive chemotherapy on achieving complete remission and overall survival among patients with MDS or sAML.
Early optimal response to TKIs is associated with reductions in treatment failures, poor outcomes, progression of disease, and death.
There is a paucity of data on the use of second-generation tyrosine kinase inhibitors among pediatric patients with chronic-phase chronic myeloid leukemia.
Perspectives differ on whether ponatinib is a niche drug that should be reserved for younger patients.
Quizartinib — an investigational FLT3 inhibitor — is the first agent in its class to demonstrate improved overall survival.
Ivosidenib is the first-in-class FDA approval for IDH1 mutation-harboring acute myeloid leukemia.
Clinical stage determined by the Binet staging system could be an accurate response surrogate among patients with chronic lymphocytic leukemia.
A large, long-term study found a 97% event-free survival rate at 18 months.
For the single-treatment STAT2 phase 2 study, researchers enrolled 96 Japanese patients with chronic myeloid leukemia who had achieved a deep molecular response during the consolidation phase of treatment with nilotinib.
Individuals at high risk of developing AML can be identified years before symptoms appear, a new study reports.
Investigators sought to evaluate the efficacy of enasidenib among older patients with untreated acute myeloid leukemia, a population that is associated with poor therapeutic outcomes.
Disease recurrence remained low among patients with CML who reduced or discontinued TKI therapy after achieving major response.
Researchers randomly assigned previously untreated patients with CD20-positive CLL to receive obinutuzumab plus chlorambucil, rituximab plus chlorambucil, or chlorambucil alone.
The effect of CAR-T therapy in acute myeloid leukemia has yet to be fully explored.
ENESTfreedom Study Reports Durable Treatment-Free Remission in Chronic Myeloid Leukemia After 96 WeeksJune 25, 2018
Nearly half of patients with CML who achieved a deep molecular response following treatment with nilotinib remained in remission for 96 weeks.
CLL/SLL characterized by del(17p) — a cytogenetic abnormality that develops over the course of the disease — is difficult to treat and responds very poorly to chemoimmunotherapy.
Bosutinib is a dual Src/Abl tyrosine kinase inhibitor approved for newly diagnosed CP-CML and relapsed/refractory CML.
Data from a previous study supports treatment-free remission as a new treatment goal for patients with chronic-phase chronic myeloid leukemia.
There are some clinical data to support a potential for increased risk of additional solid organ malignancies in patients with CML.
Men have approximately double the incidence rate, are more likely to have progressive and treatment-resistant disease, and have a poorer prognosis compared with women with CLL.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Despite Promising Trial Results, Skeptics Raise Red Flags About Anlotinib's Efficacy in Heavily Treated NSCLC
- Higher Risk of MGUS in Relatives of Patients With Multiple Myeloma Confirmed
- Brentuximab Vedotin Combo Active in Older Patients With Hodgkin Lymphoma
- Prostate Cancer Drug Resistance Mediated by Epigenetic Changes
- Nilotinib and Dasatinib Confer Similar Outcomes for Chronic-Phase CML